Athos Capital Ltd Purchases Shares of 99,200 Catalent, Inc. (NYSE:CTLT)

Athos Capital Ltd bought a new stake in Catalent, Inc. (NYSE:CTLT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 99,200 shares of the company’s stock, valued at approximately $6,009,000. Catalent makes up approximately 1.9% of Athos Capital Ltd’s investment portfolio, making the stock its 8th biggest position. Athos Capital Ltd owned approximately 0.05% of Catalent at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CTLT. Dynamic Technology Lab Private Ltd purchased a new position in shares of Catalent in the 3rd quarter worth approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after purchasing an additional 14,373 shares during the period. Quest Partners LLC boosted its holdings in shares of Catalent by 289.8% in the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock worth $2,986,000 after buying an additional 36,652 shares during the last quarter. Swedbank AB bought a new stake in Catalent in the first quarter worth about $1,659,000. Finally, Citigroup Inc. increased its stake in shares of Catalent by 26.2% during the 3rd quarter. Citigroup Inc. now owns 204,923 shares of the company’s stock worth $12,412,000 after purchasing an additional 42,517 shares during the last quarter.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by company insiders.

Catalent Trading Up 0.2 %

NYSE CTLT opened at $61.11 on Monday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock’s 50-day simple moving average is $59.90 and its two-hundred day simple moving average is $58.51. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.50. The company has a market capitalization of $11.09 billion, a price-to-earnings ratio of -27.04, a PEG ratio of 2.43 and a beta of 1.16.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business earned ($0.10) earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. Research analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat.com, Catalent presently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.